US FDA outlines broad vision for advancing regulatory science
This article was originally published in SRA
A new report outlining the US Food and Drug Administration's "broad vision" for advancing regulatory science focuses on seven public health areas that pose the most pressing challenges facing citizens1,2.
You may also be interested in...
A new draft guideline explains how sponsors of subsequent-entry orally inhaled drug products can comply with the Canadian requirement for demonstrating equivalence to the reference product.
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”